Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 11, 2022

SELL
$1.73 - $4.06 $5,861 - $13,755
-3,388 Closed
0 $0
Q4 2021

Jan 21, 2022

SELL
$3.5 - $5.68 $1,722 - $2,794
-492 Reduced 12.68%
3,388 $15,000
Q3 2021

Nov 12, 2021

BUY
$3.44 - $6.37 $13,347 - $24,715
3,880 New
3,880 $20,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $111M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.